ライフサイエンスコーパス: pectoris

1 coronary syndrome (82 MI, 44 unstable angina pectoris).

2 pectoris in most patients with stable angina pectoris.

3 ith ischemic heart disease and stable angina pectoris.

4 erse outcomes in patients with stable angina pectoris.

5 ms and myocardial perfusion in stable angina pectoris.

6 ndovascular approach in the relief of angina pectoris.

7 r combined CHD death/nonfatal MI plus angina pectoris.

8 cases of fatal CHD; and 124 cases of angina pectoris.

9 ocardial infarction (MI) and unstable angina pectoris.

10 e reserve in patients with refractory angina pectoris.

11 9%) men and 41 (5.2%) women developed angina pectoris.

12 ge less than the duration of unstable angina pectoris.

13 develop in association with unstable angina pectoris.

14 firmed acute myocardial infarction or angina pectoris.

15 ed incident coronary events including angina pectoris.

16 roses in other patients with unstable angina pectoris.

17 e clinical manifestations of unstable angina pectoris.

18 ignificance in patients with unstable angina pectoris.

19 0 cases of fatal CHD, and 60 cases of angina pectoris.

20 symptoms in patients with refractory angina pectoris.

21 ith sympathetic phenotypes, including angina pectoris.

22 ciation exists between edentulism and angina pectoris.

23 nd 673,810 (2.3%) were diagnosed with angina pectoris.

24 ere more likely to be associated with angina pectoris.

25 4 cases of fatal CHD, and 68 cases of angina pectoris.

26 ith myocardial infarction or unstable angina pectoris.

27 atment for ischaemia in patients with angina pectoris.

28 nction, congestive heart failure, and angina pectoris.

29 d for the treatment of chronic stable angina pectoris.

30 chronic heart failure, and in stable angina pectoris.

31 approach to the treatment of chronic angina pectoris.

32 er acute coronary syndromes or stable angina pectoris.

33 ssion in patients with chronic stable angina pectoris.

34 -term outcome in patients with stable angina pectoris.

35 or patients with chronic, symptomatic angina pectoris.

36 rapeutic approach to the treatment of angina pectoris.

37 ns exist for patients with refractory angina pectoris.

38 d to be normal and those with typical angina pectoris.

39 een patients with unstable and stable angina pectoris.

40 ith new-onset chest pain or worsening angina pectoris.

41 ith new-onset chest pain or worsening angina pectoris.

42 5%, a prior myocardial infarction; 5% angina pectoris; 2.3%, intermittent claudication; and 7%, a car

43 Angina pectoris affects at least 6.6 million people in the US a

44 ted the efficacy of TMR for relieving angina pectoris, although no study to date has specifically add

45 A total of 95 patients with angina pectoris and angiographically documented coronary artery

46 ily for treatment of hypertension and angina pectoris and are thought to act as allosteric modulators

47 pective trial patients with suspected angina pectoris and at least one cardiovascular risk factor wer

48 in subjects with personal history of angina pectoris and familial aneurysm.

49 Secondary endpoints were angina pectoris and hospitalization for heart failure.

50 d significantly activated in unstable angina pectoris and is not affected by severity of CAD or medic

51 Male patients (n = 328) with stable angina pectoris and ischemia on treadmill testing were randomly

52 erate drinking decreases the risk for angina pectoris and myocardial infarction in apparently healthy

53 tion, 10 angina pectoris, and 12 both angina pectoris and myocardial infarction) after the diagnosis

54 y atherosclerotic lesions, leading to angina pectoris and myocardial infarction, damages the heart, r

55 onary heart disease, including stable angina pectoris and the acute coronary syndromes.

56 opulation of patients with refractory angina pectoris and to present the therapeutic options currentl

57 events (11 myocardial infarction, 10 angina pectoris, and 12 both angina pectoris and myocardial inf

58 s of hypertension, diabetes mellitus, angina pectoris, and atrial fibrillation provides even more int

59 ar disorders, including hypertension, angina pectoris, and cardiac arrhythmia.

60 rdial infarction, functional class of angina pectoris, and hospitalizations for unstable angina.

61 nonfatal acute myocardial infarction, angina pectoris, and ischemic heart failure.

62 oronary revascularization procedures, angina pectoris, and sudden CHD deaths.

63 of patients (94%) had class III or IV angina pectoris, and two patients (6%) had unstable symptoms pr

64 with stable angina pectoris, unstable angina pectoris,and ST-segment elevation myocardial infarction.

65 se (CHD); myocardial infarction (MI); angina pectoris; and performance of coronary bypass or angiopla

66 eserved ejection fraction (HFpEF) and angina pectoris (AP).

67 Although angina pectoris appears to be related statistically to subnorma

68 After we excluded isolated angina pectoris as an initial event, the lifetime risk of coron

69 Cardiac amyloidosis can present as angina pectoris associated with coronary flow reserve abnormali

70 pendent proportional hazards methods; angina pectoris at 5 years was modeled using univariate and mul

71 of nonfatal myocardial infarction and angina pectoris at 5 years, even after consideration of powerfu

72 of nitroglycerin in the treatment of angina pectoris began not long after its original synthesis in

73 ts in 60-90% of diseases that include angina pectoris, bronchial asthma, herpes simplex, and duodenal

74 Non-cardiac chest pain mimics angina pectoris but generally originates from the oesophagus.

75 antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controv

76 tory ischemia in patients with stable angina pectoris, but it remains to be established whether suppr

77 ascular event (myocardial infarction, angina pectoris, cerebrovascular accidents, or major coronary s

78 ew episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke.

79 ction, CHD death, angiogram-confirmed angina pectoris, coronary artery bypass graft surgery, stents,

80 time risks of coronary heart disease (angina pectoris, coronary insufficiency, myocardial infarction,

81 n medical therapy for men with stable angina pectoris due to single-vessel disease.

82 Twenty developed angina pectoris during pacing, while 21 did not.

83 Angina pectoris during RCA occlusion tended to occur in fewer p

84 oronary ECG ST-segment elevation, and angina pectoris during the same 1-minute coronary occlusion.

85 d duration of clinical improvement in angina pectoris following TMR.

86 se tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited into a d

87 In patients with suspected stable angina pectoris, global longitudinal peak systolic strain asses

88 Patients with MI and unstable angina pectoris had higher VEGF levels compared with stable ang

89 k Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eastern Eu

90 Postprandial angina pectoris has been recognized for more than two centuries

91 ine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-fre

92 coronary vein grafts and uncontrolled angina pectoris have limited options for therapy.

93 evascularization, hospitalization for angina pectoris, hospitalization for congestive heart failure,

94 ality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or do

95 used extensively in the treatment of angina pectoris, hypertension, and arrhythmia.

96 The indication for PTCA was stable angina pectoris in 69 patients, unstable angina in 22 and acute

97 The standard liquid meal precipitated angina pectoris in all patients.

98 of association between edentulism and angina pectoris in Mexican adults aged 35 years and older.

99 sponsible for myocardial ischemia and angina pectoris in most patients with stable angina pectoris.

100 The standard liquid meal induced angina pectoris in patients with coronary artery disease.

101 TMR improved the functional class of angina pectoris in patients with end stage coronary artery dise

102 Stable angina pectoris in women has often been considered a "soft" dia

103 lar events (myocardial infarction and angina pectoris) in 498 women with systemic lupus erythematosus

104 D progression in patients with stable angina pectoris is associated with increased C-reactive protein

105 Refractory angina pectoris is defined, and traditional medical therapies a

106 to the risk for other events, such as angina pectoris, is not known.

107 50 diseases monitored, a single one, angina pectoris, is significantly elevated (3.3x) in iciHHV-6+

108 n network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for th

109 ] for every 0.26 mmol/L increase) and angina pectoris (multivariate odds ratio, 1.049 [95% confidence

110 focal microscope x z - scanning of cutaneous pectoris muscle fibres varied linearly with [1/extracell

111 the neuromuscular junction of frog cutaneous pectoris muscle.

112 to assess risk for a first CHD event (angina pectoris, myocardial infarction, or cardiac death) alone

113 7.9 years, 76 subjects developed CEs (angina pectoris, myocardial infarction, or coronary death).

114 5 subjects developed coronary events (angina pectoris, myocardial infarction, or coronary death): 21

115 tion (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age categories.

116 otide and neurotransmitter in frog cutaneous pectoris nerve-muscle preparations.

117 ents with clinically suspected stable angina pectoris, no previous cardiac history, and normal left v

118 treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneous or su

119 treatment of myocardial ischemia and angina pectoris not amenable to conventional percutaneous or su

120 lf-reported QoL parameters related to angina pectoris, notably in terms of angina frequency and disea

121 ial infarction, but the prevalence of angina pectoris, of smoking, and of chest pain in the attack wa

122 Angina pectoris often results from ischemic episodes that excit

123 t failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary artery d

124 of presentation with either unstable angina pectoris or acute myocardial infarction.

125 ican region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent, more a

126 scularization, or with a diagnosis of angina pectoris or CHD defined by angiography.

127 ation of symptoms in patients who had angina pectoris or myocardial infarctions.

128 of 1473 patients with either unstable angina pectoris or non-Q-wave myocardial infarction (NQWMI) enr

129 and less likely to have a history of angina pectoris (OR 0.58, 95% CI 0.34-0.99) compared with non-R

130 brillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class s

131 had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction.

132 defined as new myocardial infarction, angina pectoris, or stroke, which developed between baseline an

133 We studied 124 chronic stable angina pectoris patients (84 men; mean age, 61+/-10 years) who

134 est in patients with suspected stable angina pectoris predicts the presence of coronary artery diseas

135 Candidates with angina pectoris, previous myocardial infarction, or congestive

136 tch-off hours in patients with stable angina pectoris receiving a beta-adrenergic blocking agent or c

137 performed in patients with refractory angina pectoris reduces ischemic wall motion abnormalities and

138 CHD, including myocardial infarction, angina pectoris, revascularization, and coronary death, occurre

139 nary angiography for suspected stable angina pectoris (SAP) (n = 4131) and an independent cohort of p

140 eferred for angiography due to stable angina pectoris (SAP) or acute coronary syndrome (ACS).

141 on AMI and unstable angina, or stable angina pectoris (SAP).

142 tion myocardial infarction and stable angina pectoris , similar patterns were found albeit less prono

143 t self-reported CHD (heart attack and angina pectoris), stroke, peripheral vascular disease, and diab

144 , all with significant improvement in angina pectoris that appears both rapid and sustained.

145 outcomes in patients with refractory angina pectoris treated with transmyocardial laser revasculariz

146 the best available therapy group) and angina pectoris (two [3%] of 74 in the ruxolitinib group vs non

147 nfarction (MI) (n = 205) and unstable angina pectoris (UAP) (n = 185).

148 l infarction (MI) (n =57) or unstable angina pectoris (UAP) (n =60) were consecutively recruited toge

149 Patients (n=141) with stable angina pectoris undergoing PCI had serial venous blood samples

150 Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation

151 es in patients presenting with stable angina pectoris, unstable angina pectoris,and ST-segment elevat

152 Overall improvement in angina pectoris was sustained at 1 year by at least one functio

153 Women with angina pectoris were less likely to undergo cardiac catheteriza

154 e duration of the episode of unstable angina pectoris were observed in 6 of 21 patients who died afte

155 going coronary angiography for stable angina pectoris were studied.

156 catheter-based therapy for refractory angina pectoris when bypass surgery or angioplasty is not possi

157 an operative treatment for refractory angina pectoris when bypass surgery or percutaneous translumina

158 We observed a patient with unstable angina pectoris who developed foci of ischemic necroses in the

159 e observed in 10 patients with stable angina pectoris, with well-defined single vessel coronary arter

160 ated using CT images of patients with angina pectoris without known valvular disease (n = 95).

161 However, in the group with angina pectoris, women were considerably less likely to undergo